Do PPAR ūĚõĺ Ligands Suppress the Growth of Cholangiocarcinoma or the Cholangiohepatitis Induced by the TumorReportar como inadecuado




Do PPAR ūĚõĺ Ligands Suppress the Growth of Cholangiocarcinoma or the Cholangiohepatitis Induced by the Tumor - Descarga este documento en PDF. Documentaci√≥n en PDF para descargar gratis. Disponible tambi√©n para leer online.

PPAR ResearchVolume 2008 2008, Article ID 587401, 4 pages

Review ArticleDepartment of Aging Medicine and Geriatrics, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

Received 5 February 2008; Accepted 9 June 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Satoru Suzuki and Kiyoshi Hashizume. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Cholangiocarcinoma is a predominantly fatal cancer, which can be difficult to treat. It has been reported that the administration of pioglitazone temporarily improved not only diabetic control, but also bile duct carcinoma-induced cholangiohepatitis. Pioglitazone is considered to have both direct and indirect mechanisms of action on the tumor-related hepatitis. Several molecules induced by thiazolidinedione, including Smad pathway-related molecules, adipokines, and other lipid metabolism-related proteins, may directly or indirectly suppress tumor development and-or tumor-induced cholangiohepatitis. Although the most frequent and critical side effect of thiazolidinedione is drug-induced hepatitis, it can probably be avoided by careful monitoring of serum hepatic enzyme levels. Thiazolidinedione should be considered for management of tumor-induced hepatitis in the presence of diabetes unless severe side effects occur.





Autor: Satoru Suzuki and Kiyoshi Hashizume

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados